Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to shrink ovarian tumors before surgery

NCT ID NCT06890338

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 11 times

Summary

This study tests whether giving the targeted drug mirvetuximab soravtansine together with standard chemotherapy (carboplatin) before surgery can shrink advanced ovarian, fallopian tube, or peritoneal cancers that have a specific protein (FRα). About 140 adults with stage III or IV disease will receive the combination every 3 weeks for up to 9 cycles. The goal is to see how many tumors respond before surgery, while also monitoring side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mirvetuximab soravtansine (MIRV) combined with carboplatin
What this could lead to
If successful, this combination could shrink advanced ovarian tumors before surgery, potentially improving surgical outcomes and delaying disease progression.
What could go wrong
This is an early Phase 2 study with no control group, so results are preliminary. The treatment may cause side effects like fatigue, nausea, or infusion reactions, and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Feb 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2. * Be judged by the investigator and/or treating physician to be an appropriate candidate to receive neoadjuvant chemotherapy. * Diagnosis of biopsy-confirmed high-grade, serous epithelial ovarian, fallopian tube or primary peritoneal cancer. * Participant meets the following disease criteria: * Stage III or IV disease by the Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) staging system, and * Folate Receptor Alpha (FRα) expression positivity as defined by immunohistochemical staining of \>= 75% of viable tumor cells with moderate \>= 2+ membrane staining by the Ventana Folate Receptor Alpha (VENTANA FOLR1) assay, FOLR1 Eligibility Testing - Ventana FOLR1 (FOLR1-2.1) RxDx - Commercial or Central, and * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria. Exclusion Criteria: * Endometrioid, clear cell, mucinous, or sarcomatous tumor histology; mixed tumors containing any of the above histologies; or low-grade/borderline ovarian tumor. * Previous clinical diagnosis of noninfectious interstitial lung disease, including noninfectious pneumonitis. * Previously treated with anticancer therapy including chemotherapy, radiation therapy, immunotherapy, or biologic agent for current cancer, with the exception of one cycle of single agent carboplatin * Participants with the following ocular history and/or concurrent disorders: * History of corneal transplantation; * Undergoing active postoperative management for refractive surgery, cataract surgery, corneal cross-linking, or corneal complications of surgery; * Confluent superficial punctate keratopathy (SPK) not expected to resolve to non-confluence or better within the screening window with standard of care (SOC) intervention; * Active or chronic clinically significant (\>= Grade 3) corneal dystrophy (e.g., Fuchs dystrophy); * Active ocular conditions requiring ongoing treatment/monitoring, such as glaucoma, which is not adequately controlled with medication or surgery, wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema or an ocular condition with high risk of retinal detachment; * Monocular vision with visual acuity in the worse eye, worse than 20/200 or visual fields less than 20 degrees (i.e., functional blindness in at least one eye). * History of other malignancy within 3 years prior to signing study consent. -- Note: Participants with tumors with a negligible risk for metastasis or death (e.g., adequately controlled basal-cell carcinoma or squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast) are eligible.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Epithelial ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Carcinoma, Ovarian Epithelial fallopian tube cancer fallopian tube neoplasm ovarian carcinoma ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Epithelial ovarian cancer Fallopian tube cancer Neoadjuvant Primary peritoneal cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    69 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atrium Health Levine Cancer Institute /ID# 274557

    RECRUITING

    Charlotte, North Carolina, 28204, United States

  • Atrium Health Wake Forest Baptist Medical Center /ID# 276952

    RECRUITING

    Winston-Salem, North Carolina, 27157, United States

  • Avera Cancer Institute - Sioux Falls /ID# 276226

    RECRUITING

    Sioux Falls, South Dakota, 57105, United States

  • Baptist Health Lexington /ID# 275218

    RECRUITING

    Lexington, Kentucky, 40503, United States

  • California Pacific Medical Center - Van Ness Campus /ID# 275329

    RECRUITING

    San Francisco, California, 94109, United States

  • Carilion Roanoke Memorial Hospital /ID# 274684

    RECRUITING

    Roanoke, Virginia, 24014, United States

  • Carle Foundation Hospital /ID# 276470

    RECRUITING

    Urbana, Illinois, 61801, United States

  • Cleveland Clinic - Cleveland /ID# 276133

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Cleveland Clinic - Cleveland /ID# 278273

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Cleveland Clinic - Cleveland /ID# 278274

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Compass Oncology - West - Tigard /ID# 275101

    RECRUITING

    Tigard, Oregon, 97223, United States

  • Cox Medical Center South /ID# 274826

    RECRUITING

    Springfield, Missouri, 65807, United States

  • Danbury Hospital, Western Connecticut Health Network /ID# 274783

    RECRUITING

    Danbury, Connecticut, 06810, United States

  • Dartmouth-Hitchcock Medical Center /ID# 274676

    RECRUITING

    Lebanon, New Hampshire, 03756, United States

  • East Carolina University - Brody School of Medicine /ID# 275770

    RECRUITING

    Greenville, North Carolina, 27834, United States

  • Good Samaritan Hospital Medical Center /ID# 274938

    RECRUITING

    West Islip, New York, 11795, United States

  • Holy Cross Hospital /ID# 275872

    RECRUITING

    Silver Spring, Maryland, 20910, United States

  • Holy Name Medical Center /ID# 276240

    RECRUITING

    Teaneck, New Jersey, 07666, United States

  • Houston Methodist Hospital /ID# 274568

    RECRUITING

    Houston, Texas, 77030, United States

  • Imbert Cancer Center /ID# 275634

    RECRUITING

    Bay Shore, New York, 11706, United States

  • Indiana University Melvin and Bren Simon Cancer Center /ID# 275492

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 276456

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • John Theurer Cancer Center /ID# 275756

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Jupiter Medical Center /ID# 276616

    RECRUITING

    Jupiter, Florida, 33458, United States

  • Kettering Medical Center /ID# 274365

    RECRUITING

    Kettering, Ohio, 45429, United States

  • Mercy David C. Pratt Cancer Center /ID# 275655

    RECRUITING

    St Louis, Missouri, 63141, United States

  • Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780

    RECRUITING

    Saint Louis Park, Minnesota, 55416, United States

  • Metrohealth Medical Center - Cleveland /ID# 276664

    RECRUITING

    Cleveland, Ohio, 44109, United States

  • Mount Sinai Medical Center /ID# 274868

    RECRUITING

    Miami Beach, Florida, 33140, United States

  • Northwell Health Cancer Institute At Huntington /ID# 276814

    RECRUITING

    Greenlawn, New York, 11740, United States

  • Northwell Health Center for Advanced Medicine. /ID# 275641

    RECRUITING

    Lake Success, New York, 11042, United States

  • Northwell Health Queens Cancer Center /ID# 274850

    RECRUITING

    Rego Park, New York, 11374, United States

  • Norton Cancer Institute - St. Matthews /ID# 276173

    RECRUITING

    Louisville, Kentucky, 40207, United States

  • Norwalk Hospital /ID# 274561

    RECRUITING

    Norwalk, Connecticut, 06856, United States

  • OSF St. Francis Medical Center /ID# 274752

    RECRUITING

    Peoria, Illinois, 61637-0001, United States

  • Oncology Associates of Oregon, P.C. /ID# 275006

    RECRUITING

    Eugene, Oregon, 97401, United States

  • Optimum Clinical Research Group /ID# 274583

    RECRUITING

    Albuquerque, New Mexico, 87109, United States

  • Parkview Research Center /ID# 274338

    RECRUITING

    Fort Wayne, Indiana, 46845, United States

  • Providence Sacred Heart Medical Center & Children'S Hospital /ID# 274585

    RECRUITING

    Spokane, Washington, 99204, United States

  • Ridley Tree Cancer Center /ID# 275219

    ACTIVE_NOT_RECRUITING

    Santa Barbara, California, 93105, United States

  • Rush Md Anderson Cancer Center /ID# 274926

    RECRUITING

    Chicago, Illinois, 60607, United States

  • Rutgers Cancer Institute of New Jersey /ID# 274358

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Sanford Cancer Center /ID# 274901

    RECRUITING

    Sioux Falls, South Dakota, 57104, United States

  • Sanford Fargo Medical Center - Fargo /ID# 275489

    RECRUITING

    Fargo, North Dakota, 58102, United States

  • Scripps Md Anderson - Prebys Cancer Center /ID# 276891

    RECRUITING

    San Diego, California, 92103, United States

  • St. Lukes University Hospital /ID# 274362

    RECRUITING

    Bethlehem, Pennsylvania, 18015, United States

  • Texas Oncology - Austin Central /ID# 275046

    RECRUITING

    Austin, Texas, 78731, United States

  • Texas Oncology - Fort Worth Cancer Center /ID# 275043

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • Texas Oncology - Northeast Texas /ID# 275057

    RECRUITING

    Tyler, Texas, 75702, United States

  • Texas Oncology - San Antonio Medical Center - Research Drive /ID# 275090

    RECRUITING

    San Antonio, Texas, 78240, United States

  • Texas Oncology - The Woodlands /ID# 275015

    RECRUITING

    The Woodlands, Texas, 77380, United States

  • The Center Of Hope /ID# 274313

    RECRUITING

    Reno, Nevada, 89511, United States

  • The Mark H Zangmeister Center /ID# 275106

    RECRUITING

    Columbus, Ohio, 43219, United States

  • Trials 365 /ID# 274310

    RECRUITING

    Shreveport, Louisiana, 71103, United States

  • UVA Health University Hospital /ID# 275309

    RECRUITING

    Charlottesville, Virginia, 22903, United States

  • University Medical Center New Orleans /ID# 274755

    RECRUITING

    New Orleans, Louisiana, 70112, United States

  • University Of Mississippi Medical Center /ID# 276342

    RECRUITING

    Jackson, Mississippi, 39216, United States

  • University of Alabama at Birmingham (UAB) Hospital /ID# 274793

    RECRUITING

    Birmingham, Alabama, 35294, United States

  • University of California Los Angeles Medical Center /ID# 274566

    RECRUITING

    Los Angeles, California, 90095, United States

  • University of Chicago Medical Center /ID# 274796

    RECRUITING

    Chicago, Illinois, 60637, United States

  • University of Maryland, Baltimore /ID# 275308

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • University of Minnesota - Minneapolis /ID# 275718

    RECRUITING

    Minneapolis, Minnesota, 55455-0341, United States

  • University of North Carolina Medical Center /ID# 275307

    RECRUITING

    Chapel Hill, North Carolina, 27514, United States

  • University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 275612

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Usa Mitchell Cancer Institute /ID# 276022

    RECRUITING

    Mobile, Alabama, 36604, United States

  • Virginia Oncology Associates- Norfolk (Brock) /ID# 275227

    RECRUITING

    Norfolk, Virginia, 23502-2800, United States

  • West Virginia University School of Medicine /ID# 274556

    RECRUITING

    Morgantown, West Virginia, 26506, United States

  • Women & Infants Hospital /ID# 274716

    RECRUITING

    Providence, Rhode Island, 02905, United States

  • Women'S Cancer Care /ID# 276469

    RECRUITING

    Covington, Louisiana, 70433, United States

  • Yale University School of Medicine /ID# 275794

    RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.